Stay updated with breaking news from Good Research Practice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LSHTM maintains a governance framework comprising a range of principles, policies, procedures and guidelines that regulate our research. This has been developed in accordance with national guidance. Research governance The Research Governance Committee oversees research governance matters across LSHTM, including the policy on Good Research Practice.
Share this article Share this article SHANGHAI, April 8, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr. Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr. Manuel Hidalgo, Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, to its Scientific Advisory Board. Drs. Rowinsky and Hidalgo will bring their strong expertise in translational and clinical...
Shanghai Genchem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies SHANGHAI, April 6, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, today announced the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed global biopharmaceutical company, to develop and commercialize multiple bi-specific antibodies (BsAb) based on monoclonal antibody developed by Genechem and antibodies selected by I-MAB. "This collaboration is the first of man...
[December 28, 2020] iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (âiBioâ or the âCompanyâ), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (âCSOâ), effective January 18, 2020. âWe are thrilled to have Dr. Brenner join our team,â said Tom Isett, Chairman & CEO of iBio. âGiven his prior experience leading organizations with novel protein exp...